Asymmetric dimethylarginine(ADMA)is a nitric oxide synthase(NOS)inhibitor.ADMA is formed by methylation of L-arginine residues.It innbits the formation of vasoactive substances(nitric oxide),resulting in endothelial dysfunction and vaseular diseases.A number of studies have suggested that ADMA may be a risk factor for stroke.The expression of ADMA increases significantly in patients with hyperhomocysteinemia,carotid stenosis and cardiovascular disease.

In 1990,the concept of microembolic signal (MES) was put forward by Spencer et al for the first time.In 1995,the expert consensus of diagnostic criteria for MES was published in Stroke.Since then,microemboli detection had been widely used as the intraoperative monitoring indicators in cerebral angiography,intravascular stenting,and carotid endarterectomy for the prevention of thrombotic events in patients with carotid artery stenosis.In recent years,microemboli detection has become an evaluation means for carotid stenosis surgery,interventional treatment and drug antithrombotic therapy.

Intracranial atherosclerotic stenosis mostly occurs in Asians,blacks and Hispanicsis,which is the most important reason for the occurrence and recurrence of ischemic stroke.The current studies mainly concentrate on the aspect of the relationship between the intracranial atherosclerotic stenosis and the traditional risk factors.With the development of genetic technology,the relationship between the genetic factors and intracranial atherosclerotic stenosis has also received increasing attention.This article reviews the advances in research on the traditional risk factors for intraeranial atherosclerotic stenosis and genetic research.

The incidence of early neurological deterioration of acute ischemic stroke is higher and the clinical prognosis is poor.There are no effective prevention and treatment measures yet.The prognosis may be improved if early predicts by serum biomarkers and actively manages.This article reviews the serum biomarkers of early neurological deterioration in ischemic stroke.

The mechanisms underlying early neurological deterioration (END) after ischemic stroke are not clear.There are no reliable predictive factors and effective preventive measures for END.The glutamatemediated excitotoxicity plays a very important role in the cascade reaction of ischemic events.High level of glutamate in plasma is one of the important predictors for END.Studies have shown that the polymorphism in the promoter of the excitatory amino acid transporter-2 gene is a potential cause for individual susceptibility to END.Some therapeutic strategies of interrupting the glutamatergic pathways may be as the strategies of intervention END.

Local intra-arterial thrombolysis has better efficacy in treating acute ischemic stroke, including cardiogenic embolism, and the safety of combined intravenous and intra-arterial thrombolysis is higher. Recent studies have suggested that the combination of angioplasty and local intra-arterial thrombolysis plays an important role in the treatment of acute ischemic stroke during an acute emergency.

The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases have close connection with the initiation, progression and progn osis of various malignancies. Recently, several approaches such as monoclonal an tibodies, bispecific antibodies, low molecular weight tyrosine kinase inhibitors and gene therapy targeting the EGFR family of receptors for anti-tumor therapy have been developed, some of which are currently undergoing clinical trials. Th ey are generally well tolerated, and have shown encouraging clinical efficacy in a variety of tumor types.

Current anti-hepatoma agents in clinical aplication have not been proved to be satisfactory. The major obstacles are low efficacy, toxicity, and drug resistance. Identifying new drug targets and discovering new agents accordin gly with high efficacies and low toxicities have become the key part of the solu tion. Recent studies have shown that hyper-methylation of tumor suppressor gene s, interaction between hepatocyte growth factor and its receptor, vascular endothelial growth factor and its receptor, as well as cyclooxygenase-2 might be potential targets for hepatomachemotherapy. Indeed, agents acting on these targets have shown to be effective. In addition, other agents such as As 2O 3 have also shown th eir activities against hepatoma.

APOBEC3 is a class of cytidine deaminase, which is considered as a new member of the innate immune system, and APOBEC3G belongs to this family. The research about APOBEC3G is a new direction of innate immune defense mechanism against virus. APOBEC3G has the restrictive activity on many viral replications, which deaminates dC to dU in the viral genome and then induces extensive hypermutation. APOBEC3G can also interrupt viral replication at several phases such as reverse transcription, replication, nucleocapsid and so on by non-deamination mechanisms. However, virus can encode viral proteins to counteract the restriction activity of APOBEC3G. Elucidation of the antagonistic interaction between APOBEC3G and the virus will be contributed to development of new antiviral drugs in the future.

Animal model is very important for anti-EV71 (enterovirus 71) drug and vaccine development. 1-day-old suckling EV71 mouse model is the main in vivo model used in China. 1-day-old suckling EV71 mouse is too small to perform antiviral experiment. And the route of administration and dosage capacity are also restricted. A strong virulence EV71 virus strain was selected after screening from five EV71 strains with 1-day-old suckling mice. A mouse-adapted EV71 strain with increased virulence in 12-day-old suckling mice, EV71-M5, was generated after five serial passages of the parental EV71 strain in mice. Virus titers of EV71 infected mice heart, liver, spleen, lung, kidney, small intestine, brain and muscle tissue were determined by cytopathic effect (CPE) assay. The virus used in this model is the first isolated EV71 strain in China. And 2-week-old suckling mice were used in this model. This is a supplement for the EV71 animal model in China. Establishment of this EV71 model will provide an attractive platform for anti-EV71 vaccine and drug development.